Evidence map›Paper›PMID 23925707›Full record

ArticleJournal of medical virology2013

Variability of the preC/C region of hepatitis B virus genotype A from a South African cohort predominantly infected with HIV.

Simnikiwe H Mayaphi, Desmond J Martin, M Jeffrey Mphahlele, Jason T Blackard, Sheila M Bowyer

Abstract read
In one paragraph

Article in Journal of medical virology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.2field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Hepatitis B virus infection in post-vaccination South Africa: occult HBV infection and circulating surface gene variants.Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology · 2015
    Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 2 countries.

Simnikiwe H MayaphiDepartment of Medical Virology, University of Pretoria/Tshwane Academic Division of NHLS, Pretoria, South Africa. smayaphi@absamail.co.za
Desmond J Martin
M Jeffrey Mphahlele
Jason T Blackard
Sheila M Bowyer
Tshwane University of Technology · ZANational Health Laboratory Service · ZAUniversity of Cincinnati Medical Center · USUniversity of Pretoria · ZA

Funding

Occult Hepatitis B Infection in South African HIV PatientsR21AI096958 · NIAID · UNIVERSITY OF CINCINNATI · PI BLACKARD, JASON T · 2011 to 2012
$412k
NIAID NIH HHS R21 AI096958
6 · The paper itself

Abstract

Hepatitis B virus (HBV) is a serious global health problem, and HBV genotype is an important determinant of disease progression and treatment outcome. The aim of this study was to assess variations of the precore/core (preC/C) region in HBV genotype A. Sequencing of the preC/C and surface (S) genes of HBV was performed on plasma samples from 20 HBV/HIV co-infected and 5 HBV mono-infected individuals. All preC/C study sequences clustered with subgenotype A1, except for two which clustered with subgenotype D4 reference strains. The nucleotide and amino acid variability was far higher in the preC/C region than in the S region. Mutations associated with reduction or failure of HBV e-antigen (HBeAg) production were observed, with a preC start codon mutation being common (24%). Other mutations (e.g., P5H/L and I97L) associated with severe liver disease were also noticed, some of which were located in the major histocompatibility restricted sites. PreC/C intergenotype nucleotide divergence was >7%, while subgenotypes differed by 2.5-7%. Several study sequences were highly divergent from other African subgenotype A1 strains. This study showed that HBeAg-negative chronic hepatitis B is underestimated in subgenotype A1, and also highlighted the variant South African A1 strains. The major advantage of preC/C sequencing is that it informs patient management as HBeAg-negative chronic hepatitis B responds poorly to conventional interferon-α therapy, and some guidelines treat HBeAg-negative chronic hepatitis B differently from HBeAg-positive chronic hepatitis B. These data suggest that subgenotype A1 may be more involved in severe HBV-related diseases.

Indexed as

Genetic VariationAdultCluster AnalysisCohort StudiesDNA, ViralFemaleGenotypeHepatitis B, ChronicHepatitis B Core AntigensHepatitis B e AntigensHepatitis B Surface AntigensHepatitis B virusHIV InfectionsHumansMaleMiddle AgedDNA, ViralHepatitis B Core AntigensHepatitis B e AntigensHepatitis B Surface Antigensamino acidsgenotypingHBeAg-negative chronic hepatitis Bmutationsnucleotides

Identifiers

PMID23925707
PMCPMC4559853
OpenAlexW2153496188

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.